Advertisement

CNS Drugs

, Volume 29, Issue 9, pp 801–809 | Cite as

N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study

  • Jerome Sarris
  • Georgina Oliver
  • David A. Camfield
  • Olivia M. Dean
  • Nathan Dowling
  • Deidre J. Smith
  • Jenifer Murphy
  • Ranjit Menon
  • Michael Berk
  • Scott Blair-West
  • Chee H. Ng
Short Communication

Abstract

Background

Obsessive-compulsive disorder (OCD) is a disabling mental illness for which pharmacological and psychosocial interventions are all too often inadequate. Recent preclinical and clinical studies have implicated dysfunction of glutamatergic neurotransmission in the pathophysiology of OCD. The amino acid-based nutraceutical N-acetyl cysteine (NAC) is a safe and readily available agent that has been found to modify the synaptic release of glutamate in subcortical brain regions via modulation of the cysteine-glutamate antiporter.

Objective

The aim of this study was to assess the efficacy and safety of NAC in treating OCD.

Methods

A 16-week, double-blind, placebo-controlled, randomised trial using 3 g/day of NAC (1.5 g twice daily) in 44 participants (aged 18–70 years) with Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5)-diagnosed OCD, during 2013–2015. The primary outcome measure was the Yale–Brown Obsessive Compulsive Scale (YBOCS), conducted every 4 weeks.

Results

Analysis of the full sample (intention-to-treat) with repeated measures mixed linear modelling revealed a nonsignificant time × treatment interaction for the YBOCS scale total score (p = 0.39). A per-protocol analysis removing protocol violators also failed to show a significant time × treatment interaction for YBOCS total score (p = 0.15). However, a significant time × treatment interaction was observed for the YBOCS ‘Compulsions’ subscale in favour of NAC (p = 0.013), with a significant reduction observed at week 12 (dissipating at week 16). At 16 weeks, only four (20 %) participants were considered ‘responders’ (YBOCS ≥35 % reduction at endpoint) versus four (27 %) in the placebo group. The NAC was well-tolerated, aside from more cases of heartburn occurring compared with placebo (p = 0.045).

Conclusion

Further research involving NAC for OCD may require larger samples to detect moderate or small effect sizes, involve dosage or formulation differences, use in concert with exposure therapy, or an additional post-study observational period to mitigate study withdrawal.

Trial Registration

ACTRN12613000310763.

Keywords

Pathological Gambling Trichotillomania Hamilton Anxiety Rate Scale Subcortical Brain Region Obsessive Compulsive Spectrum Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The NAC was kindly donated and supplied by Bioceuticals®, Alexandria, NSW, Australia. Jerome Sarris is funded by a CR Roper Fellowship, and Michael Berk is supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship 1059660.

Compliance with Ethical Standards

This study was given ethics approval by The Melbourne Clinic Ethics Committee (TMC_HREC no. 219), which is an NHMRC registered Ethics Committee in Australia, and was conducted according to the 1964 Declaration of Helsinki. All participants freely gave informed consent before commencing the study.

Funding

No funding was received for the conduct of this study or the preparation of this manuscript. The NAC and placebo tablets were supplied free of charge by Bioceuticals (this company does not currently sell this product; additionally, they had no involvement in study design/conduct/data analysis/publication of results).

Conflict of interest

No specific conflicts are identified from any individual author. Jerome Sarris has received honoraria, research support, royalties, and consultancy or travel grant funding from Bioceuticals, Blackmores, Taki Mai, Integria Health Pepsico, HealthEd, Soho-Flordis, Pfizer, Elsevier, the Society for Medicinal Plant and Natural Product Research, CR Roper Fellowship, The NHMRC, and Chaminade University. Olivia M. Dean is a Research Fellow and has received grant support from the Brain and Behavior Foundation, Simons Autism Foundation, Australian Rotary Health, Stanley Medical Research Institute, Deakin University, Brazilian Society Mobility Program, Lilly, NHMRC and an Australasian Society for Bipolar Disorders/Servier grant. She has also received in-kind support from BioMedica Nutraceuticals, Nutrition Care and Bioceuticals. Chee Ng has previously received research support from Wyeth and Lundbeck, and speaker honoraria from Servier, Bristol-Myers Squibb, Organon, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Astra-Zenaca, Wyeth, and Pfizer. Michael Berk has received grant/research support from the National Institutes of Health, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, Medical Benefits Fund, NHMRC, Beyond Blue, Rotary Health, Geelong Medical Research Foundation, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Meat and Livestock Board, Organon, Novartis, Mayne Pharma, Servier and Woolworths, has been a speaker for Astra-Zeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay and Wyeth, and served as a consultant to Astra-Zeneca, Bioadvantex, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck Merck and Servier, and is a co-inventor on two provisional patents regarding the use of NAC and related compounds for psychiatric indications assigned to the Mental Health Research Institute. Georgina Oliver, David A. Camfield, Nathan Dowling, Deidre J. Smith, Jenifer Murphy, Ranjit Menon, and Scott Blair-West have no conflicts of interest to declare.

References

  1. 1.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): American Psychiatric Association; 2013.Google Scholar
  2. 2.
    Ting JT, Feng G. Neurobiology of obsessive-compulsive disorder: insights into neural circuitry dysfunction through mouse genetics. Curr Opin Neurobiol. 2011;21(6):842–8.PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Harrison BJ, Pujol J, Cardoner N, et al. Brain corticostriatal systems and the major clinical symptom dimensions of obsessive-compulsive disorder. Biol Psychiatry. 2013;73(4):321–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Rotge JY, Guehl D, Dilharreguy B, et al. Meta-analysis of brain volume changes in obsessive-compulsive disorder. Biol Psychiatry. 2009;65(1):75–83.CrossRefPubMedGoogle Scholar
  5. 5.
    Rotge JY, Langbour N, Jaafari N, et al. Anatomical alterations and symptom-related functional activity in obsessive-compulsive disorder are correlated in the lateral orbitofrontal cortex. Biol Psychiatry. 2010;67(7):e37–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Milad MR, Rauch SL. Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways. Trends Cogn Sci. 2012;16(1):43–51.CrossRefPubMedGoogle Scholar
  7. 7.
    Ahmari SE, Spellman T, Douglass NL, et al. Repeated cortico-striatal stimulation generates persistent OCD-like behavior. Science. 2013;340(6137):1234–9.PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Pittenger C, Bloch MH, Williams K. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther. 2011;132(3):314–32.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Wu K, Hanna GL, Rosenberg DR, et al. The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacol Biochem Behav. 2012;100(4):726–35.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Kariuki-Nyuthe C, Gomez-Mancilla B, Stein D. Obsessive compulsive disorder and the glutamate system. Curr Opin Psychiatry. 2014;27:32–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Yucel M, Wood SJ, Wellard RM, et al. Anterior cingulate glutamate-glutamine levels predict symptom severity in women with obsessive-compulsive disorder. Aust N Z J Psychiatry. 2008;42(6):467–77.CrossRefPubMedGoogle Scholar
  12. 12.
    Bhattacharyya S, Khanna S, Chakrabarty K, et al. Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder. Neuropsychopharmacology. 2009;34(12):2489–96.CrossRefPubMedGoogle Scholar
  13. 13.
    Chakrabarty K, Bhattacharyya S, Christopher R, et al. Glutamatergic dysfunction in OCD. Neuropsychopharmacology. 2005;30(9):1735–40.CrossRefPubMedGoogle Scholar
  14. 14.
    Burdo J, Dargusch R, Schubert D. Distribution of the cystine/glutamate antiporter system xc- in the brain, kidney, and duodenum. J Histochem Cytochem. 2006;54(5):549–57.CrossRefPubMedGoogle Scholar
  15. 15.
    Ersan S, Bakir S, Erdal Ersan E, et al. Examination of free radical metabolism and antioxidant defence system elements in patients with obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(6):1039–42.CrossRefPubMedGoogle Scholar
  16. 16.
    Ozdemir E, Cetinkaya S, Ersan S, et al. Serum selenium and plasma malondialdehyde levels and antioxidant enzyme activities in patients with obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(1):62–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Behl A, Swami G, Sircar SS, et al. Relationship of possible stress-related biochemical markers to oxidative/antioxidative status in obsessive-compulsive disorder. Neuropsychobiology. 2010;61(4):210–4.CrossRefPubMedGoogle Scholar
  18. 18.
    Chakraborty S, Singh OP, Dasgupta A, et al. Correlation between lipid peroxidation-induced TBARS level and disease severity in obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(2):363–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Moran MM, McFarland K, Melendez RI, et al. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci. 2005;25(27):6389–93.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Choy KH, Dean O, Berk M, et al. Effects of N-acetyl-cysteine treatment on glutathione depletion and a short-term spatial memory deficit in 2-cyclohexene-1-one-treated rats. Eur J Pharmacol. 2010;649(1–3):224–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Berk M, Malhi GS, Gray LJ, et al. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci. 2013;34(3):167–77.CrossRefPubMedGoogle Scholar
  22. 22.
    Deepmala, Slattery J, Kumar N, et al. Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review. Neurosci Biobehav Rev. 2015;55:294–321.Google Scholar
  23. 23.
    Atkuri K, Mantovani J, Herzenberg L. N-Acetylcysteine a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol. 2007;7(4):355–9.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2009;66(7):756–63.CrossRefPubMedGoogle Scholar
  25. 25.
    Grant JE, Kim SW, Odlaug BL. N-Acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry. 2007;62(6):652–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Ghanizadeh A, Derakhshan N, Berk M. N-Acetylcysteine versus placebo for treating nail biting, a double blind randomized placebo controlled clinical trial. Antiinflamm Antiallergy Agents Med Chem. 2013;12(3):223–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Afshar H, Roohafza H, Mohammad-Beigi H, et al. N-Acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2012;32(6):797–803.CrossRefPubMedGoogle Scholar
  28. 28.
    Berk M, Copolov DL, Dean O, et al. N-Acetyl cysteine for depressive symptoms in bipolar disorder—a double-blind randomized placebo-controlled trial. Biol Psychiatry. 2008;64(6):468–75.CrossRefPubMedGoogle Scholar
  29. 29.
    Berk M, Copolov D, Dean O, et al. N-Acetyl cysteine as a glutathione precursor for schizophrenia—a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008;64(5):361–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Garcia RJ, Francis L, Dawood M, et al. Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65(5):1313–8.PubMedCentralCrossRefPubMedGoogle Scholar
  31. 31.
    Goodman W. The Yale-Brown obsessive compulsive scale. Arch Gen Psychiatry. 1989;46:1006–11.CrossRefPubMedGoogle Scholar
  32. 32.
    CGI: Clinical Global Impressions. In: Guy W, Bonato R, editors. Manual for the ECDEU Assessment Battery. 2nd revised edition. Chevy Chase: National Institute of Mental Health;1970. p. 121–126.Google Scholar
  33. 33.
    Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50–5.CrossRefPubMedGoogle Scholar
  34. 34.
    Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Goldberg D. Manual of the General Health Questionnaire. Windsor: NFER Publishing; 1978.Google Scholar
  36. 36.
    Ruscio AM, Stein DJ, Chiu WT, et al. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry. 2010;15(1):53–63.PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    Amen SL, Piacentine LB, Ahmad ME, et al. Repeated N-acetyl cysteine reduces cocaine seeking in rodents and craving in cocaine-dependent humans. Neuropsychopharmacology. 2011;36(4):871–8.PubMedCentralCrossRefPubMedGoogle Scholar
  38. 38.
    Oliver G, Dean O, Camfield D, et al. N-Acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review. Clin Psychopharmacol Neurosci. 2015;13(1):12–24.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Jerome Sarris
    • 1
    • 2
  • Georgina Oliver
    • 1
  • David A. Camfield
    • 2
    • 6
    • 7
  • Olivia M. Dean
    • 3
    • 5
  • Nathan Dowling
    • 1
  • Deidre J. Smith
    • 1
  • Jenifer Murphy
    • 1
  • Ranjit Menon
    • 1
  • Michael Berk
    • 3
    • 4
    • 5
  • Scott Blair-West
    • 1
  • Chee H. Ng
    • 1
  1. 1.Department of Psychiatry, The Melbourne ClinicThe University of MelbourneMelbourneAustralia
  2. 2.Centre for Human PsychopharmacologySwinburne UniversityMelbourneAustralia
  3. 3.IMPACT Strategic Research Centre, School of MedicineDeakin University, Barwon HealthGeelongAustralia
  4. 4.Orygen, The National Centre of Excellence in Youth Mental Health and the Centre for Youth Mental HealthMelbourneAustralia
  5. 5.Florey Institute for Neuroscience and Mental HealthMelbourneAustralia
  6. 6.Illawarra Health and Medical Research InstituteWollongongAustralia
  7. 7.School of PsychologyUniversity of WollongongWollongongAustralia

Personalised recommendations